Rebecca Stone, MD
Obstetrics & Gynecology · Baltimore, MDNPI 1033324793
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $80,023 of the $87,986 with a category attached, or 91.0%. AstraZeneca accounts for 96.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $35,278 and has fallen 99.0% since, to $340 in 2025. Among obstetrics & gynecology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $2666.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$85K
- GSK$2K
- Applied Medical Resources Corporation$1K
- Johnson & Johnson$237
- Boston Scientific$116
- Merck$40
Across 4 payments — averaging $13,760 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pacira Pharmaceuticals Incorporated$38K
- AstraZeneca$17K
What the payments were for
- Consulting fees$80,02391%
- Speaking & faculty fees$6,4007%
- Travel & lodging$9921%
- Food & beverage$4881%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $84,539 |
| GSK | 2 | $2,044 |
| Applied Medical Resources Corporation | 3 | $1,011 |
| Johnson & Johnson | 9 | $237 |
| Boston Scientific | 3 | $116 |
| Merck | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,986 in reported general payments places this provider in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $11,550 |
| Estradiol | 24 | $6,019 |
| Letrozole | 35 | $592 |
| Tamoxifen Citrate | 22 | $471 |
| Norethindrone Acetate | 14 | $458 |
| Megestrol Acetate | 13 | $184 |
| Ondansetron Hcl | 17 | $74 |
| Pantoprazole Sodium | 14 | $55 |
| Prednisone | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Baltimore
- Danielle ShillerBaltimore$221K
- Karen WangBaltimore$91K
- Christina EnzmannBaltimore$63K
- Latasha MurphyBaltimore$41K
- Ishrat RafiBaltimore$29K
- Colleen McCormickBaltimore$29K
- Jenell ColemanBaltimore$18K
- David MatthewsBaltimore$12K
- Anne BurkeBaltimore$12K
- Michelle KushBaltimore$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.